Adamis Pharmaceuticals to Present at Two Upcoming Conferences
GlobeNewswire - Tue Dec 02, 8:01AM CST
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced that the Company is scheduled to present a company overview at two upcoming conferences.
ADMP: 5.17 (+0.06)
Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014
M2 - Tue Dec 02, 6:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/53cpct/chronic) has announced the addition of the "Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and special features on late-stage and discontinued projects. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD) - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: 100 companies are cited in this text including: - Ache Laboratorios Farmaceuticos S/A - Adamis Pharmaceuticals Corporation - Advinus Therapeutics Ltd. - AIM Therapeutics Inc. - Axikin Pharmaceuticals, Inc. - Basilea Pharmaceutica AG - Daiichi Sankyo Company, Limited - Errant Gene Therapeutics, LLC - Five Prime Therapeutics, Inc. - GlaxoSmithKline plc - Hydra Biosciences, Inc. - iCeutica, Inc. - Johnson & Johnson - KaloBios Pharmaceuticals, Inc. - Medestea Research & Production S.p.A. - Novartis AG - Ockham Biotech Limited - Pfizer Inc. - PharmaLundensis - Re-Pharm - Seoul Pharma - Takeda Pharmaceutical Company - Zambon Company For more information visit http://www.researchandmarkets.com/research/53cpct/chronic
JNJ: 104.59 (+0.31), KBIO: 1.63 (-0.04), PFE: 31.42 (-0.03), ADMP: 5.17 (+0.06), GSK: 42.85 (+0.11), NVS: 93.91 (+0.66), FPRX: 26.12 (+0.07)
Contraception - Pipeline Review, H2 2014
M2 - Mon Dec 01, 3:08AM CST
Research and Markets (http://www.researchandmarkets.com/research/rzn2sh/contraception) has announced the addition of the "Contraception - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Contraception, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Contraception and special features on late-stage and discontinued projects. This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from This proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by This team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Contraception - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Contraception pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Actavis - Adamis Pharmaceuticals - Agile - ANI - Antares - Bayer - Evofem - HRA Pharma - Hydra Biosciences - Intas - Ligand - Merck & Co - Orbis Biosciences - Pantarhei Bioscience - Teva Pharmaceutical Industries For more information visit http://www.researchandmarkets.com/research/rz...traception
MRK: 57.46 (+0.25), ADMP: 5.17 (+0.06), TEVA: 57.09 (+0.33)
Global Herpes Simplex Infections Therapeutics Pipeline Report H2 2014 - Analysis of 31 Companies & 46 Drug Profiles
M2 - Mon Nov 10, 10:43AM CST
Research and Markets (http://www.researchandmarkets.com/research/lk8z5n/herpes_simplex) has announced the addition of the "Herpes Simplex Infections - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Herpes Simplex Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Herpes Simplex Infections and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Sanofi - GenVec, Inc. - Astellas Pharma Inc. - CEL-SCI Corporation - Mymetics Corporation - NovaBay Pharmaceuticals, Inc. - Peregrine Pharmaceuticals, Inc. - Oryzon Genomics S.A. - Colby Pharmaceutical Company - ViroStatics, srl - Osel Inc. - AlphaVax, Inc. - Romark Laboratories, L.C. - Chimerix, Inc. - NanoBio Corporation - Immunovaccine, Inc. - Immune Design Corp. - Seek - Adamis Pharmaceuticals Corporation - Vaxart, Inc. - Genocea Biosciences, Inc. - Pharis Biotec GmbH - Profectus BioSciences, Inc. - 3-V Biosciences, Inc. - PaxVax - Spider Biotech - Kala Pharmaceuticals, Inc. - Vaccibody AS - Sanofi Pasteur SA - Humabs BioMed SA Drug Profiles - amenamevir - GEN-003 - herpes simplex virus vaccine - HSV-529 - brincidofovir - CEL-1000 - Vaccine for Herpes Simplex Infections - herpes simplex vaccine [HSV-2] - C-31G - Cyanovirin-N for Infectious Disease - GEN-002 - NVC-727 - NVC-638 - NVC-704 - JVRS-100 Herpes Simplex Virus-2 Vaccine - Drug for Herpes Simplex - PGN-632 - G-103 - GV-2207 - acyclovir - SB-105 - Monoclonal Antibodies for HIV and Herpes Simplex Infections - Synthetic Peptide for Oncology and Infectious Disease - herpes simplex virus vaccine - MB-66 - Small Molecule to Inhibit Fatty Acid Synthase for Viral Infections - BA-368 - HSV-2 Vaccine - Small Molecule Inhibiting Kinases for Viral Infections - mab hu2c For more information visit http://www.researchandmarkets.com/research/lk...es_simplex
IMDZ: 34.96 (+0.78), CMRX: 36.80 (+0.70), CVM: 0.62 (+0.03), ADMP: 5.17 (+0.06), GNCA: 7.42 (-0.11)
Adamis Pharmaceuticals Announces Key Additions to Medical and Commercial Teams
GlobeNewswire - Wed Oct 15, 8:35AM CDT
Adamis Pharmaceuticals Corporation (Nasdaq:ADMP) today announced key additions to its medical and product marketing management teams. These new employees position the company for further development of its product pipeline and the preparation of a sales and marketing plan for the anticipated launch of its epinephrine pre-filled syringe for treatment of allergic reactions (Type I) including anaphylaxis.
ADMP: 5.17 (+0.06)
Market Maker Surveillance Report. IDN, VII, ISNS, DGLY, MGT, ADMP, Winning Stocks With Lowest Price Friction For Tuesday, September 2nd 2014
M2 - Thu Sep 04, 9:47AM CDT
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 4916 companies with "abnormal" market making, 2511 companies with positive Friction Factors and 2570 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. Intellicheck Mobilisa Inc (NYSE:IDN), Vicon Industries Inc (NYSE:VII), Image Sensing Systems Inc (NASDAQ:ISNS), Digital Ally Inc (NASDAQ
MGT: 0.60 (-0.01), ADMP: 5.17 (+0.06), ISNS: 2.77 (+0.04), VII: 1.83 (+0.38), DGLY: 15.62 (+0.82), IDN: 3.04 (+0.03)
Adamis Pharmaceuticals Announces Appointment of New Members to Its Board of Directors
Marketwire - Tue Aug 26, 6:15AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the appointment of Richard C. Williams, Robert B. Rothermel and William C. Denby to its Board of Directors. Mr. Williams was also appointed as Chairman of the Board.
ADMP: 5.17 (+0.06)
Adamis Pharmaceuticals raises USD5m from private placement of convertible preferred stock
M2 - Wed Aug 20, 9:24AM CDT
Biopharmaceutical company Adamis Pharmaceuticals (NASDAQ:ADMP) revealed on Tuesday the issuance of 1,418,439 shares of Series A convertible preferred stock to a fundamental healthcare institutional fund for gross cash proceeds of about USD5m in a private placement.
ADMP: 5.17 (+0.06)
Adamis Pharmaceuticals Announces Private Placement
eTeligis - Tue Aug 19, 4:15PM CDT
SAN DIEGO, CA, United States, via ETELIGIS INC., 08/19/2014 - - Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that it has completed a private placement financing transaction pursuant to which it issued 1,418,439 shares of Series A Convertible Preferred Stock to a fundamental healthcare institutional fund and received gross cash proceeds of approximately $5,000,000.The preferred stock is convertible into common stock at a conversion ratio of 1-to-1 at the option of the investor and has no preference to the common shares.The Company also issued to the investor warrants to purchase a number of shares of common stock equal to the number of shares of preferred stock purchased by the investor.The warrants, which are exercisable for a period of five years, have an exercise price of $3.40 per share and are callable for cash.
ADMP: 5.17 (+0.06)
Adamis Pharmaceuticals' NDA for EPINEPHRINE INJECTION, USP accepted for US FDA's review
M2 - Wed Jul 30, 5:42AM CDT
Biopharmaceutical company Adamis Pharmaceuticals (NASDAQ:ADMP) reported on Tuesday the US Food and Drug Administration's (FDA) acceptance of its New Drug Application (NDA) for EPINEPHRINE INJECTION, USP, 1:1000 for review for the emergency treatment of allergic reactions (Type I) including anaphylaxis.
ADMP: 5.17 (+0.06)
FDA Accepts for Review Adamis' New Drug Application for Its Epinephrine Pre-Filled Syringe
Marketwire - Tue Jul 29, 8:15AM CDT
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) for the product, EPINEPHRINE INJECTION, USP, 1:1000 (0.3 mg Pre-filled single dose syringe) (PFS), for the emergency treatment of allergic reactions (Type I) including anaphylaxis.
ADMP: 5.17 (+0.06)
Global Contraceptives Market 2014-2018 with Actavis, Bayer AG, J&J's, Janssen Pharma, Merck & Co., Pfizer, & Teva Pharmaceutical Leading the Way
M2 - Tue Jul 08, 10:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/d964b9/global) has announced the addition of the "Global Contraceptives Market 2014-2018" report to their offering. The global contraceptives market is set to grow at a CAGR of 5.90 percent over the period 2013-2018. The Global Contraceptives market is driven by several factors, of which the growing prevalence of unplanned pregnancies is one of the major drivers. In order to control the 41 percent of unplanned pregnancies out of 208.2 million pregnancies globally, there has been an increase in the number of initiatives by governments and NGOs. Furthermore, the report states that one of the major challenges is the introduction of low-cost generic contraceptives. Recently, pharmaceutical companies have introduced new products into their portfolios or diversified their contraceptive drugs and devices. This trend has been primarily supported by several prominent deals or partnerships to develop or introduce new products with better efficacy and safety profiles. These strategic decisions will help companies to generate revenue and acquire a significant share of the Global Contraceptives market. Some of the major acquisitions in this space include Conceptus Inc. by Bayer, Warner Chilcott plc by Actavis, Uteron Pharma SA by Watson Pharmaceuticals Inc., and Barr Pharmaceuticals Inc. by Teva Pharmaceutical Industries. Some of the other prominent deals include Bayer and USAID partnering to make Microgynon, an oral contraceptive and Starpharma Holdings licensing agreement with Okamoto Industries Inc. for the VivaGel-coated condom. The global contraceptives market can be segmented broadly into two divisions: Drugs and Devices. This report covers the present scenario and the growth prospects of the Global Contraceptives market for the period 2013-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for contraception which include: - Drugs (Oral Contraceptive Pills, Injectable Contraceptives, Topical Contraceptives) - Devices (Male & Female condoms, Diaphragms, IUDs, Vaginal Rings, Female Sponges and Subdermal Contraceptive Implants) Key Vendors: - Actavis plc - Bayer AG - Johnson & Johnson's Janssen Pharmaceuticals, Inc. - Merck & Co. - Pfizer, Inc. - Teva Pharmaceutical Industries, Ltd Other Prominent Vendors: - Adamis Pharmaceuticals Corp. - Agile Therapeutics, Inc. - ANI Pharmaceuticals, Inc. - Ansell Ltd. - Apothecus Pharmaceutical Corp. - Blairex Laboratories Inc. - Church & Dwight, Co. Inc. - Caldwell Consumer Health, LLC. - Ferring International Center S.A - Fuji Latex Co., Ltd. - HLL Lifecare Limited - Mayer Laboratories - Medicines 360 - Karex Berhad - Lipocine Inc. - Lupin Pharmaceuticals, Inc. - Mylan Laboratories Inc. - Okamoto Industries, Inc. - Pantarhei Bioscience B.V. - Paul Hartmann AG - Reckitt Benckiser Group Plc - The Female Health Company For more information visit http://www.researchandmarkets.com/research/d964b9/global
CHD: 80.16 (-0.37), PFE: 31.42 (-0.03), ADMP: 5.17 (+0.06), MYL: 56.97 (+0.39), JNJ: 104.59 (+0.31), ANIP: 55.24 (+1.79), MRK: 57.46 (+0.25), LPCN: 5.15 (+0.01), TEVA: 57.09 (+0.33)
Adamis Pharmaceuticals Announces Investor Update Live Webcast
Marketwire - Thu Jun 12, 7:10AM CDT
Adamis Pharmaceuticals Corp. (NASDAQ: ADMP) ("the Company"
ADMP: 5.17 (+0.06)